Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's Disease Acitretin Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mild to moderate AD (NINCDS-ADRDA criteria)~* Mini-Mental State Examination (MMSE): 27-14 points~* Geriatric Depression Scale ≤ 14~Exclusion Criteria:~* hereditary cognitive impairment~* known history of brain injuries~* Insufficient German language skills~* actual treatment with other potential disease modifying drugs of AD~* multimorbidity or significant organ (esp. liver or renal) dysfunction~* evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)~* contraindication to acitretin such as osteoporosis, hypoalbuminaemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acitretin (Type: ACTIVE_COMPARATOR): oral, 30 mg per day, day 1-28
- Placebo (Type: PLACEBO_COMPARATOR): oral, day 1-28

Based on this trial design, predict the completion outcome and termination type (if applicable).